New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of precision biologics for the treatment of age-related diseases, announced that it has been chosen to participate in the New York State pavilion at the BIO International Convention, the world’s largest and most influential event for the pharmaceutical and biotechnology industry being held June 5-8 in Boston. The participation of Manhattan Bio at the New York pavilion is sponsored by the New York State Center for Biotechnology (CFB) at Stony Brook University.
“We are honored to have been selected as one of the participants in the New York State pavilion at this year’s BIO International Convention,” said Manhattan Bio Chief Executive Officer Borys Shor, Ph.D. “We are grateful for the support of the CFB and look forward to showcasing our latest work, and connecting with leaders in the biotech industry.”
The CFB has expressed its pleasure in supporting Manhattan Bio and two other biotech companies to be part of this year’s New York State pavilion at BIO. “The BIO event offers a tremendous platform for companies around the world to explore partnerships with universities, businesses, and the investment community,” said Diane Fabel, Ph.D., Director of Operations for the CFB. “We are thrilled to support client companies to participate in the event to spotlight the innovative science and business happening in New York State.”
About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of biologic immunotherapies that target host defense pathways for the treatment of age-related diseases. The company has established partnerships with the National Institutes of Health (NIH), Stony Brook University, Binghamton University, The University at Buffalo, INSERM, and EVQLV and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation, and Technology (CSIT) and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT).
About the Center for Biotechnology
Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology, and Innovation (NYSTAR) Center for Advanced Technology. The CFB serves as an important catalyst in the development of new biomedical technology and emerging companies in New York State. Through groundbreaking initiatives, the CFB supports technology commercialization and company formation by bridging the gap between discovery and commercial success and training the next generation of biomedical leaders. The CFB also supports New York’s biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the state. The CFB has contributed to the development of more than a dozen FDA-approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others, as well as supporting the formation or development of dozens of emerging bioscience companies.
Contact for investor inquiries
Jordana Lovett, PhD
Director of Investor Relations